Journal ArticleDOI
Intravitreal ranibizumab and/or dexamethasone implant for macular edema secondary to retinal vein occlusion.
Sylvia Nghiem-Buffet,Franck Fajnkuchen,Marc Buffet,Sandrine Ayrault,Anna Le Gloahec-Lorcy,Typhaine Grenet,Corinne Delahaye-Mazza,Gabriel Quentel,Salomon Y. Cohen +8 more
TLDR
Both intravitreal ranibizumab and dexamethasone intravtreal implant could be used as first-line therapy for patients with ME secondary to retinal vein occlusion in a clinical setting.Abstract:
Purpose: To investigate the outcome of intravitreal ranibizumab and/or dexamethasone implant treatment for treatment of macular edema (ME) secondary to central orread more
Citations
More filters
Journal ArticleDOI
Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex®) in its treatment
Justus G. Garweg,Souska Zandi +1 more
TL;DR: In patients with chronic macular edema not responsive to repetitive anti-VEGF therapies, the outcome after dexamethasone implant treatment is encouraging, but these results are achieved at the expense of side effects typically associated with steroids.
Journal ArticleDOI
Twelve-month outcomes in patients with retinal vein occlusion treated with low-frequency intravitreal ranibizumab.
TL;DR: Even with a low number of injections during the introductory period, there were still improvements in both visual acuity and CMT in RVO patients after 12 months, indicating that it was an effective treatment.
Journal ArticleDOI
Comparison of intravitreal dexamethasone implant and anti-VEGF drugs in the treatment of retinal vein occlusion-induced oedema: a meta-analysis and systematic review
TL;DR: Compared with anti-VEGF agents, DEX implant required fewer injections but had inferior functional efficacy and safety and the latter achieved comparable efficacy with a 4-month dosage interval.
Journal ArticleDOI
Low frequency ranibizumab versus dexamethasone implant for macular oedema secondary to branch retinal vein occlusion.
TL;DR: The aim was to make a real‐world comparison of the efficacy of ranibizumab, dexamethasone and grid laser treatments in macular oedema due to branch retinal vein occlusion (BRVO).
Journal ArticleDOI
The short-term efficacy of intravitreal ranibizumab, aflibercept and dexamethasone implant in the treatment of macular edema due to non-ischemic central retinal vein occlusion
TL;DR: IR and IA may be preferred treatment for ME due to non-ischemic CRVO as visual improvement remains the primary ophthalmological objective and the most important advantages of IDI are its effect on CMT and the need for fewer injections.
References
More filters
Journal ArticleDOI
Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders
Lloyd Paul Aiello,Robert L. Avery,Paul G. Arrigg,B A Keyt,Henry D. Jampel,Sweta Shah,Louis R. Pasquale,Hagen Thieme,Mami Iwamoto,John Edward Park +9 more
TL;DR: The data suggest that VEGF plays a major part in mediating active intraocular neovascularization in patients with ischemic retinal diseases, such as diabetic retinopathy and retinal-vein occlusion.
Journal ArticleDOI
Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.
David M. Brown,Peter A. Campochiaro,Rishi P. Singh,Zhengrong Li,Sarah Gray,Namrata Saroj,Amy Chen Rundle,Roman G. Rubio,Wendy Yee Murahashi +8 more
TL;DR: Intraocular injections of 0.3 mg or 0.5 mg ranibizumab provided rapid improvement in 6-month visual acuity and macular edema following CRVO, with low rates of ocular and nonocular safety events.
Journal ArticleDOI
Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.
Julia A. Haller,Francesco Bandello,Rubens Belfort,Mark S. Blumenkranz,Mark C Gillies,Jeffrey S. Heier,Anat Loewenstein,Young-Hee Yoon,Marie-Louise Jacques,Jenny Jiao,Xiao-yan Li,Scott M. Whitcup +11 more
TL;DR: In this paper, the safety and efficacy of dexamethasone intravitreal implant (DEX implant; OZURDEX, Allergan, Inc., Irvine, CA) compared with sham in eyes with vision loss due to macular edema (ME) associated with BRVO or central retinal vein occlusion (CRVO).
Journal ArticleDOI
Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion
Peter A. Campochiaro,Jeffrey S. Heier,Leonard Feiner,Sarah Gray,Namrata Saroj,Amy Chen Rundle,Wendy Yee Murahashi,Roman G. Rubio +7 more
TL;DR: Intraocular injections of 0.3 mg or 0.5 mg ranibizumab provided rapid, effective treatment for macular edema following BRVO with low rates of ocular and nonocular safety events and no new safety events were identified in patients with BRVO.
Journal ArticleDOI
A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Observation to Treat Vision Loss Associated With Macular Edema Secondary to Central Retinal Vein Occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 5
Michael S. Ip,Ingrid U. Scott,Paul C. VanVeldhuisen,Neal Oden,Barbara A Blodi,Marian R. Fisher,Lawrence J. Singerman,Michael J. Tolentino,Clement K. Chan,Victor H. Gonzalez +9 more
TL;DR: Intravitreal triamcinolone is superior to observation for treating vision loss associated with macular edema secondary to CRVO in patients who have characteristics similar to those in the SCORE-CRVO trial.
Related Papers (5)
Intravitreal Dexamethasone Implant for Macular Edema in Branch Retinal Vein Occlusion According to Previous Responses to Bevacizumab
The Short-Term Efficacy of Intravitreal Ranibizumab for Macular Edema in Central Retinal Vein Occlusion
Hye Young Shin,Dong Hyun Jee +1 more